Trade Summary

2 days ago, Anzalone Christopher Richard, serving as CEO at Arrowhead Pharmaceuticals, Inc. (ARWR), sold 51,726 shares at $69.13 per share, for a total transaction value of $3,575,575.00. Following this transaction, Anzalone Christopher Richard now holds 3,805,926 shares of ARWR.

This sale represents a 1.00% decrease in Anzalone Christopher Richard's stake in the company. This is considered a medium-conviction trade.

The trade was executed on Monday, December 29, 2025 and publicly disclosed via SEC Form 4 filing on Tuesday, December 30, 2025, 1 day after the trade was made.

Arrowhead Pharmaceuticals, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.